Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Cancer J. 2013 May-Jun;19(3):247–262. doi: 10.1097/PPO.0b013e318292e51a

Table 3.

Overview of selected vaccines studied for NSCLC therapy

Vaccine Target Component Adjuvant
L-BLP25 (Stimuvax) MUC1 MUC1 peptide Monophosphoryl lipid A
TG4010 MUC1 MUC1 peptide Recombinant viral vector expressing IL-2
MAGE-A3 MAGE-A3 MAGE-A3 full protein AS15 or AS02B adjuvant system
Belagenpumatucel-1 (Lucanix) NSCLC antigens Allogeneic tumor cells from 4 irradiated NSCLC cell lines (H460, H520, SKLU-1, RH2) TGF-β2 antisense gene modification
rHuEGF (CimaVax) EGF EGF full protein Oil emulsion ISA51